A new twice-yearly antiviral injection that can prevent HIV is likely to be approved soon in Australia. Making it affordable ...

Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 20 years ago, it would be worth $9,708.95 today based on a price of $111.70 for GILD at the time of writing.

Baltimore's beloved live music tradition, Jazzy Summer Nights is well into its 25th and final season. This farewell season, ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

The July 24 event aims to inspire accessible and impactful philanthropy by breaking down barriers to meaningful change.

A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...

This article discusses the DOJ’s growing crackdown on healthcare fraud, focusing on illegal speaker programs like Gilead’s $202 million settlement. It stresses the importance of strong compliance, ...

Rising one place to number one overall, the British drugmaker has overtaken the NHS as the preferred destination for science ...

As Gilead Sciences gets underway with the key launch of its twice-yearly pre-exposure prophylaxis (PrEP) HIV med, the company ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...